Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency

Abstract

The Clinical Assessment Program and Teflaro^® Utilization Registry (CAPTURE) is a multicenter retrospective study, conducted in the USA, describing the contemporary use of ceftaroline fosamil. Ceftaroline is primarily excreted by the kidneys and the dose should be reduced in patients with moderate to severe renal insufficiency. This article describes the clinical effectiveness of ceftaroline fosamil in the treatment of acute bacterial skin and skin structure infection (ABSSSI) or community-acquired bacterial pneumonia (CABP) patients with renal insufficiency. There were 985 ABSSSI patients and 344 CABP patients, of which 22 and 31%, respectively, had renal insufficiency. Ceftaroline fosamil was mostly administered to patients as second-line therapy. Overall clinical success was 78–91% among ABSSSI or CABP patients with renal insufficiency and, overall, >50% of patients were discharged to home. Ceftaroline fosamil is an effective treatment option for ABSSSI or CABP patients with renal insufficiency.

Keywords:

• ABSSSI
• acute bacterial skin and skin structure infection
• CABP
• CAPTURE
• ceftaroline fosamil
• community-acquired bacterial pneumonia
• registry
• renal insufficiency

Acknowledgements

The authors thank the participating sites, investigators and staff for their contributions to this study.

Financial & competing interests disclosure

CAPTURE is funded by Cerexa, Inc., a wholly owned subsidiary of Forest Laboratories, LLC. Micron Research Ltd. assisted in the preparation of the manuscript. This assistance was funded by Forest Laboratories, LLC. C Maggiore and T Pasquale are investigators for CAPTURE. P Cole and HD Friedland are employees of Cerexa, Inc., a wholly owned subsidiary of Forest Laboratories, LLC. P Cole and HD Friedland are also shareholders of Actavis plc, which acquired Forest Laboratories in July 2014. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance from Micron Research Ltd. was utilized in the production of this manuscript.

Key issues

• Acute bacterial skin and skin structure infection (ABSSSIs) and community-acquired bacterial pneumonia (CABP) are significant healthcare issues in the USA.

• Ceftaroline fosamil is a cephalosporin prodrug approved for the treatment of ABSSSIs and CABP.

• Ceftaroline fosamil is primarily excreted via the kidneys, thus the dose of ceftaroline fosamil must be lowered in patients with moderate-to-severe renal insufficiency or end-stage renal disease.

• This article describes the contemporary clinical effectiveness of ceftaroline fosamil in the USA for the treatment of ABSSSI or CABP in patients with normal renal function/mild renal insufficiency, moderate or severe renal insufficiency or end-stage renal disease.

• Data were collected retrospectively between August 2012 and February 2014 from patient charts identified from pharmacy listings.

• At least 50% of ABSSSI patients with moderate or severe renal insufficiency, or end-stage renal disease had diabetes mellitus and at least 20% had peripheral vascular disease.

• The most common medical history among CABP patients with moderate or severe renal insufficiency or end-stage renal disease was structural lung disease or gastroesophageal reflux.

• Overall clinical success was 78–91% among patients with ABSSSI, with 4% of readmissions related to ABSSSI.

• Among patients with CABP, overall clinical success was 81–91%, with 9% of readmissions related to CABP.

• Limitations of the CAPTURE study included the retrospective study design and the lack of a comparator group.

• These findings demonstrate that ceftaroline fosamil can effectively treat ABSSSI or CABP in patients with various levels of renal impairment.

Notes